Investment Partners LTD. Sells 1,847 Shares of Bristol Myers Squibb Company $BMY

Investment Partners LTD. lessened its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 12.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,591 shares of the biopharmaceutical company’s stock after selling 1,847 shares during the period. Investment Partners LTD.’s holdings in Bristol Myers Squibb were worth $583,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Trifecta Capital Advisors LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $25,000. REAP Financial Group LLC raised its stake in Bristol Myers Squibb by 202.8% in the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 428 shares in the last quarter. Accent Capital Management LLC bought a new stake in Bristol Myers Squibb in the 1st quarter valued at about $33,000. CBIZ Investment Advisory Services LLC increased its holdings in shares of Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 231 shares during the period. Finally, GKV Capital Management Co. Inc. acquired a new stake in shares of Bristol Myers Squibb in the first quarter valued at approximately $36,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Trading Up 0.2%

Shares of NYSE BMY opened at $49.17 on Thursday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The stock has a market cap of $100.11 billion, a P/E ratio of 19.83, a price-to-earnings-growth ratio of 2.23 and a beta of 0.33. The firm has a 50 day moving average price of $45.31 and a two-hundred day moving average price of $46.69. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were paid a $0.62 dividend. The ex-dividend date was Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 83.78%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on BMY shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a research note on Tuesday, August 5th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, October 13th. Four equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $55.45.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.09% of the stock is owned by insiders.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.